BDB001 (EIK1001) + Atezolizumab
Phase 1Completed 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tumor, Solid
Conditions
Tumor, Solid
Trial Timeline
Nov 21, 2019 โ Aug 15, 2024
NCT ID
NCT04196530About BDB001 (EIK1001) + Atezolizumab
BDB001 (EIK1001) + Atezolizumab is a phase 1 stage product being developed by Eikon Therapeutics for Tumor, Solid. The current trial status is completed. This product is registered under clinical trial identifier NCT04196530. Target conditions include Tumor, Solid.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04196530 | Phase 1 | Completed |
Competing Products
20 competing products in Tumor, Solid